All In Biotech

Drug Trial Radar · NCT07714187

A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides

A Phase 1 Dose-escalation Study of Topical Duvelisib in Patients With Early-stage Mycosis Fungoides

Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Oct 2028

Study completion Jan 2029

Sponsor

Lead sponsor
SecuraBioIndustry
Sponsor type
Industry
First posted
Jul 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and preliminary efficacy of duvelisib topical gel in participants with early-stage mycosis fungoides.

Conditions

  • Mycosis Fungoides
  • Cutaneous T-cell Lymphoma

Interventions

  • DuvelisibDrug

    Topical gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline through Day 114
  2. Local Skin Reactions to Duvelisib Topical GelTime frame: After each treatment administration up to Day 114
  3. Maximum Tolerated Dose (MTD) of Duvelisib Topical GelTime frame: Up to 28 days
  4. Recommended Phase 2 Dose (RP2D) of Duvelisib Topical GelTime frame: Up to 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins University

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.